IVA Rentabilitas dodolan reged Inventiva Corp

Lambang korporat lan logo Inventiva SA (IVA)

Inventiva S.A. is developing advanced therapies for NAFLD, where stringent FDA regulations limit the entry of new players. The reliability of research is ensured by strict control over the transportation of biomaterials. The company's strategy is based on molecule diversification and partnerships to mitigate risks. The current gross margin level demonstrates financial stability, and its latest value is recorded as -5232.80.

Inventiva (IVA) - Margin reged saka 04.07.2022 nganti 19.11.2026

Rincian metrik keuangan lan pasar Inventiva Corp (IVA)

- nilai saham lan prakiraan konsensus rega:
Ringkesan analisis perusahaan:Inventiva SA (IVA)
Produk dadi Inventiva Pharma

Gross margin determines the portion of revenue remaining after direct production costs, serving as a key metric of the issuer's operational efficiency and pricing power. Analyzing the gross margin ratio allows for an assessment of the profitability potential of Inventiva S.A. upon the market launch of lanifibranor, where high margins will provide the foundation for securing large-scale licensing agreements within the MASH therapy segment.